Marker Therapeutics, Inc. (NASDAQ: MRKR) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced a clinical update, exciting investors who are sending the stock on a run for the top. Today, we’ll talk about:
- The update;
- what we’re seeing from MRKR stock as a result; and
- what we’ll be watching for ahead.
MRKR Provides Clinical Update
As mentioned above, Marker Therapeutics is having a strong start to the trading session this morning after providing an update with regard to clinical activities. In a press release, the company announced a year-end update in five clinical trials.
In the release, MRKR reminded investors that the trials surround its therapeutic products known as LAPP and MAPP multi-antigen targeted T cell (MultiTAA) therapies and TPIV200, a Folate Receptor Alpha (FRa) peptide cancer vaccine product candidate. Of course, the update was positive, showing progress on all accounts. To view the entire update, click here.
In a statement, Peter L. Hoang, President & CEO at MRKR, had the following to offer:
We are pleased to provide an update on our progress in advancing clinical trials using our therapeutic platform… With our MultiTAA cell therapies, we continue to build on the size and depth of our patient dataset. These updates now bring our total reported number of patients to 72, up from 57 in our previously reported results. I believe this represents one of the most extensive sets of clinical results in cell therapy for cancer treatment and illustrates the potential safety and clinical effects of MultiTAA T cells for patients suffering from a number of terrible cancers.
In our vaccine program, we continue to demonstrate our commitment to excellence in our clinical execution. Last year when I joined the company, I expressed that we would work to improve our clinical efficiency, and I believe that the completion of enrollment of our FRV-004 study in ovarian cancer over six months ahead of schedule reflects our dedication to that objective. In fact, we have now completed enrollment of our last two clinical trials significantly ahead of projections, reflecting the commitment of our management and clinical team to execute multi-center studies effectively.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to Marker Therapeutics, the news proved to be overwhelmingly positive. After all, the update showed that the company is making good progress with regard to their clinical-stage pipeline. So, it’s not surprising that excited investors are pushing the stock on a run for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:23), MRKR is trading at $6.51 per share after a gain of $0.64 per share or 10.90% thus far today.
Stop wasitng your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the iWatch Markets team will continue to keep a close eye on MRKR. In particular, we’re interested in following the story surrounding the company’s continued work with regard to its impressive clinical pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the iWatch Markets mailing list below!